Sanofi reports third-quarter growth and upgrades annual financial guidance
Pharmaceutical company Sanofi recorded double-digit sales growth in the third quarter of 2026, prompting an upward revision of its full-year financial outlook.
Sanofi announced double-digit growth in both sales and business earnings per share for the third quarter of 2026. The company attributed this performance to strong market demand, leading leadership to upgrade its financial guidance for the remainder of the fiscal year.
The firm is simultaneously expanding its operational footprint, having recently broken ground on a new insulin manufacturing facility in Germany. In the research sector, Sanofi expanded its global alliance with Regeneron to develop next-generation immunology antibodies, while concurrently deciding to halt regulatory submissions for its amlitelimab candidate for atopic dermatitis.
Governance and marketing shifts are also underway, including changes to the company's executive committee and a new partnership agreement with the Tour de France. These developments, along with a strategic deal with Cheplapharm regarding mature medicines, reflect a broader push to streamline operations and focus on key therapeutic areas.